We served as lead counsel representing a national pharmaceutical ingredient supplier and its wholly-owned subsidiaries in an investigation of alleged False Claims Act (FCA) violations concerning inflated Average Wholesale Prices, kickbacks to physicians, and waivers of co-pays. After a several-year investigation based on the filing of four separate qui tams, we negotiated a successful resolution of the litigation that was far less than the government’s alleged damages of several hundred million dollars. Reported decision: U.S. ex rel. Hueseman v. PSI et al., (WDTX) and U.S. ex rel. Sten v. Midwest Compounders, et al., (NDIA).
Representation of Life Sciences Company Fagron Holding USA LLC
You Also May Be Interested In:
Representation of axialHealthcare, a care optimization platform navigating substance use issues for patients, providers, and health plans, in a $15 million Series C round of financing to accelerate its expansion into the substance use disorder (SUD) treatment, and recovery sector. Previous institutional investors Oak HC/FT, .406 Ventures, BlueCross BlueShield Venture Partners (BCBSVP), and Sandbox Advantage Fund led the round.